---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-008163"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:41:45.642916+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates

## Summary
- Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.
- Net loss for Q4 2024 was $104.6 million ($0.76 per share) vs $116.0 million ($0.86 per share) in Q4 2023.
- Phase 3 ECLIPSE registrational program in chronic hepatitis delta on track for first patient in first half of 2025.
- Initial Phase 1 data for VIR-5818 showed tumor shrinkage in 50% (10/20) of participants at doses ≥400 µg/kg.
- Company plans to initiate Phase 1 study of VIR-5525, dual-masked EGFR-targeting T-cell engager, in first half 2025.

## SEC filing metadata
- accession: 0001628280-25-008163
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008163/0001628280-25-008163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008163/vir-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-008163
- JSON: https://secwatch.observer/filing/0001628280-25-008163.json
- Plain text: https://secwatch.observer/filing/0001628280-25-008163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.